This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Large-Cap Drug Stocks To Buy Post Q1 Earnings
by Arpita Dutt
Take a look at these four large-cap drug stocks including Merck (MRK) that look well-positioned post Q1 earnings.
5 Reasons Why Merck (MRK) is a Good Stock to Buy Now
by Zacks Equity Research
It looks like a great stock to buy now.
The Zacks Analyst Blog Highlights: Merck, Barclays, Activision Blizzard, Blackstone and Tyson Foods
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Barclays, Activision Blizzard, Blackstone and Tyson Foods
3 Large Cap Drug Stocks to Buy Now
by Ryan McQueeney
Our overall "Medical" sector is up about 7.78% year-to-date, which just edges out the gains of the S&P 500. Within this broad sector, one of the better performing industries has been what we call "Large Cap Pharmaceuticals."
Celldex (CLDX) Q1 Loss In Line, Revenues Beat, Shares Up
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) posted first-quarter 2017 loss of 28 cents per share, which was in line with the Zacks Consensus Estimate
Top Ranked Income Stocks to Buy for May 10th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, May 10th:
Incyte (INCY) Q1 Loss Narrower than Expected, Revenues Beat
by Zacks Equity Research
Incyte's first-quarter results were encouraging as the company reported a narrower-than-expected loss and surpassed revenue expectations.
Merck vs. Pfizer: Which Stock Looks Better Post-Earnings?
by Zacks Equity Research
Pfizer is better positioned than Merck and thus calls for investors' attention post earnings.
Stock Market News for May 03, 2017
by Zacks Equity Research
Benchmarks finished in the green on Tuesday following the release of strong earnings reports
Drug Stock Q1 Earnings Releases on May 4: ZTS, REGN & More
by Zacks Equity Research
Here we have four pharma companies that are set to report first-quarter results on May 4. Let's see how things are shaping up for them.
Pfizer (PFE) Q1 Earnings Beat, Sales Lag, 2017 View Intact
by Zacks Equity Research
Pfizer, Inc. (PFE) reported first-quarter 2017 adjusted earnings per share of 69 cents, which beat the Zacks Consensus Estimate of 67 cents by 3%.
Merck (MRK) Beats on Earnings in Q1, Ups view
by Ekta Bagri
Merck surpassed first-quarter 2017 earnings expectations. The company reported EPS of 88 cents while our consensus called for EPS of 83 cents.
This Week's Most Spectacular Earnings Charts
by Tracey Ryniec
Tracey went through all of the earnings charts to find the best so you don't have to.
6 FDA Events to Watch Out for in May 2017
by Arpita Dutt
Here is a look at a few important regulatory events scheduled for the month of May including the FDA's decision regarding the label expansion of Merck's (MRK) Keytruda.
Seattle Genetics (SGEN) Q1 Loss Widens, Sales Top Estimates
by Zacks Equity Research
Seattle Genetics, Inc. (SGEN) reported a loss of 42 cents per share for the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 41 cents and the year-ago loss of 15 cents per share.
Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View
by Zacks Equity Research
Bristol-Myers Squibb Company's (BMY) first-quarter 2017 earnings of 84 cents per share beat the Zacks Consensus Estimate of 72 cents and surged 14% from the year-ago period.
What's in Store for Merck (MRK) this Earnings Season?
by Zacks Equity Research
Merck & Co., Inc. (MRK) will be reporting first-quarter 2017 earnings on May 2, before market opens. Last quarter, the company delivered a positive earnings surprise of 1.14%.
Bristol-Myers (BMY) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell.
What's in Store for Agenus (AGEN) this Earnings Season?
by Zacks Equity Research
Agenus Inc. (AGEN) is expected to report first-quarter 2017 results later this month or early next month.
3 Key Factors to Look Out for in Biogen's Q1 Results
by Arpita Dutt
With Biogen (BIIB) set to report Q1 results tomorrow, here is a look at 3 key factors investors will be focused on apart from earnings and revenue.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Oracle, Merck, Honeywell and Altria
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Oracle, Merck, Honeywell and Altria
J&J (JNJ) Q1 Earnings Beat Estimates, Pharma Sales Slow Down
by Zacks Equity Research
Johnson & Johnson (JNJ) reported mixed first quarter results, with earnings beating expectations while sales missing the same.
Zoetis (ZTS) Inks Agreement to Acquire Nexvet Biopharma
by Zacks Equity Research
Zoetis Inc. (ZTS) announced an agreement to buy Nexvet Biopharma plc (NVET) for an aggregate equity valuation of approximately $85 million
Dow 30 Stock Roundup: Microsoft Buys Cloud Tech Firm, Disney's "Beauty and the Beast"
by Swarup Gupta
The index experienced an eventful and holiday shortened week, marked by growing geopolitical tensions.
Bristol-Myers (BMY) Collaborates with Apexigen for Opdivo
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced a collaboration agreement with clinical-stage biopharmaceutical company Apexigen, Inc.